Received Oct 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | D4J9L | IM |
Vaccine exposure during pregnancy; This non-serious prospective pregnancy case was reported by a other health professional via sales rep and described the occurrence of vaccine exposure during pregnancy in a 35-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number D4J9L, expiry date 11-JUL-2027) for prophylaxis. On 29-SEP-2025, the patient received the 1st dose of Boostrix (intramuscular). On an unknown date, an unknown time after receiving Boostrix, the patient experienced vaccine exposure during pregnancy (Verbatim: Vaccine exposure during pregnancy). The outcome of the vaccine exposure during pregnancy was not applicable. Pregnancy exposure: Pregnancy Exposure (Boostrix): To mother in third trimester Pregnancy Details (Neonate 1): Pregnancy Outcome: Lost to follow up Delivery Notes: The patient was 33 weeks pregnant at the time of the event onset. Additional Information: GSK Receipt Date: 07-OCT-2025 A healthcare professional reported that a 35-year-old female patient, who was 33 weeks pregnant, received the vaccine, resulting in vaccine exposure during pregnancy.